Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Teams with Flanders Univ. Institute for Biotech to ID Alzheimer s Genes

NEW YORK, Aug. 30 – Galapagos Genomics and the Flanders Interuniversity Institute for Biotechnology have entered a collaboration to identify and validate Alzheimer-related gene targets, the companies announced Thursday.

Under the terms of the collaboration, Galapagos, a privately held company based in Belgium, integrate its PhenoSelect gene function discovery platform with the Flanders Interuniversity Institute for Biotechnology’s (VIB) cell-based presesilin-gamma-secretase assays to screen its human gene library for genes involved in Alzheimer’s Disease.

Financial details of the deal were not disclosed.

After identifying target genes, Galapagos plans to work with VIB to validate potential drug targets.

“This collaboration is an important step forward for us as a target discovery focused company,” Galapagos’s CEO Onno van de Stolpe said in a statement.

Earlier this month, Galapagos announced a collaboration with Vertex Pharmaceuticals to identify the function of various proteins.  In June, the company entered a partnership with Bayer Yakuhin of Japan to identify and evaluate the function of proteins associated with asthma.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.